Baxter International (NYSE:BAX) Stock Rating Upgraded by Wall Street Zen

Baxter International (NYSE:BAX) was upgraded by research analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a note issued to investors on Saturday, Wall Street Zen reports.

Several other equities analysts have also recently issued reports on BAX. Barclays started coverage on Baxter International in a report on Wednesday, October 7th. They issued an “underweight” rating and a $20.00 price target on the stock. Zacks Research raised Baxter International from a “strong sell” rating to a “hold” rating in a research report on Tuesday, August 11th. Wells Fargo & Company raised their price objective on Baxter International from $23.00 to $25.00 and gave the company an “equal weight” rating in a research report on Friday. Citigroup cut their price target on shares of Baxter International from $28.00 to $27.00 and set a “neutral” rating on the stock in a report on Monday, October 5th. Finally, UBS Group boosted their price target on shares of Baxter International from $19.00 to $25.00 and gave the stock a “hold” rating in a research note on Tuesday, July 28th. One analyst has rated the stock with a Buy rating, ten have issued a Hold rating and three have given a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Reduce” and an average price target of $23.00.

Baxter International Price Performance

NYSE BAX opened at $22.95 on Friday. The stock has a market cap of $11.87 billion, a price-to-earnings ratio of -16.28, a PEG ratio of 3.39 and a beta of 0.68. Baxter International has a 12 month low of $15.73 and a 12 month high of $30.00. The company’s 50 day moving average is $24.59 and its two-hundred day moving average is $21.37. The company has a current ratio of 1.79, a quick ratio of 1.19 and a debt-to-equity ratio of 1.20.

Baxter International (NYSE:BAX) last announced its earnings results on Thursday, October 29th. The medical instruments supplier reported $0.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.52 by $0.06. The firm had revenue of $2.98 billion for the quarter, compared to analyst estimates of $2.91 billion. Baxter International had a positive return on equity of 16.23% and a negative net margin of 6.23%. The business’s revenue was up 5.0% on a year-over-year basis. During the same quarter last year, the firm posted $0.69 EPS. As a group, research analysts anticipate that Baxter International will post 2.10 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in BAX. Jones Financial Companies Lllp bought a new position in shares of Baxter International in the 2nd quarter worth $26,000. CYBER HORNET ETFs LLC grew its holdings in shares of Baxter International by 52.4% in the 2nd quarter. CYBER HORNET ETFs LLC now owns 2,153 shares of the medical instruments supplier’s stock worth $46,000 after acquiring an additional 740 shares during the period. Community Bank N.A. acquired a new position in Baxter International in the second quarter valued at $46,000. Versant Capital Management Inc grew its stake in Baxter International by 552.2% in the second quarter. Versant Capital Management Inc now owns 2,413 shares of the medical instruments supplier’s stock worth $51,000 after purchasing an additional 2,043 shares in the last quarter. Finally, EFG International AG acquired a new position in shares of Baxter International during the 2nd quarter valued at $67,000. 90.19% of the stock is currently owned by institutional investors.

Key Baxter International News

Here are the key news stories impacting Baxter International this week:

• Positive Sentiment: Baxter reported third-quarter adjusted earnings of $0.58 per share, exceeding the $0.52 analyst consensus, while revenue increased 5% year over year to $2.98 billion and topped expectations of $2.91 billion. Growth was described as broad-based across the company’s segments. Baxter Q3 Earnings Beat on Broad-Based Growth, 2026 Outlook Raised
• Positive Sentiment: Management raised its full-year 2026 earnings outlook, signaling confidence in operating performance despite ongoing pressure on profitability. However, quarterly EPS remained below the $0.69 reported a year earlier. Baxter Raises 2026 Earnings Guidance
• Positive Sentiment: Wells Fargo raised its price target for BAX to $25 from $23, implying potential upside from recent trading levels. The firm maintained an “equal weight” rating, suggesting a constructive but cautious view. Wells Fargo Baxter Analyst Ratings
• Neutral Sentiment: Baxter declared a quarterly dividend of $0.01 per share, or $0.04 annualized. The approximately 0.2% yield provides minimal income support but maintains a cash-return program. Baxter Raises Guidance and Declares Dividend
• Negative Sentiment: The FDA issued Baxter a warning letter citing CGMP violations. The regulatory action could increase remediation costs, create operational disruptions, and raise concerns about compliance and product quality. Baxter Received FDA Warning Letter

Baxter International Company Profile

Baxter International Inc is a global medical products and healthcare technology company headquartered in Deerfield, Illinois. The company develops, manufactures and distributes products used in hospitals, clinics, ambulatory care centers and other healthcare settings.

Baxter’s portfolio has included intravenous therapies and administration systems, infusion pumps, connected-care technologies, surgical products, patient monitoring equipment and products used in medication preparation and delivery.